Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 2.30
PGNX's Cash-to-Debt is ranked lower than
69% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. PGNX: 2.30 )
Ranked among companies with meaningful Cash-to-Debt only.
PGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.3  Med: No Debt Max: No Debt
Current: 2.3
Equity-to-Asset 0.44
PGNX's Equity-to-Asset is ranked lower than
71% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. PGNX: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
PGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.24  Med: 0.87 Max: 0.98
Current: 0.44
-0.24
0.98
Debt-to-Equity 0.67
PGNX's Debt-to-Equity is ranked lower than
71% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. PGNX: 0.67 )
Ranked among companies with meaningful Debt-to-Equity only.
PGNX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.5  Med: 0 Max: 0.67
Current: 0.67
-0.5
0.67
Interest Coverage 0.25
PGNX's Interest Coverage is ranked lower than
89% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PGNX: 0.25 )
Ranked among companies with meaningful Interest Coverage only.
PGNX' s Interest Coverage Range Over the Past 10 Years
Min: 0.25  Med: No Debt Max: No Debt
Current: 0.25
Piotroski F-Score: 5
Altman Z-Score: -0.38
Beneish M-Score: -1.79
WACC vs ROIC
24.47%
5.69%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % 1.13
PGNX's Operating Margin % is ranked higher than
84% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. PGNX: 1.13 )
Ranked among companies with meaningful Operating Margin % only.
PGNX' s Operating Margin % Range Over the Past 10 Years
Min: -878.82  Med: -71.63 Max: 18.87
Current: 1.13
-878.82
18.87
Net Margin % -6.13
PGNX's Net Margin % is ranked higher than
81% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. PGNX: -6.13 )
Ranked among companies with meaningful Net Margin % only.
PGNX' s Net Margin % Range Over the Past 10 Years
Min: -876.82  Med: -64.28 Max: 15.56
Current: -6.13
-876.82
15.56
ROE % -4.30
PGNX's ROE % is ranked higher than
85% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. PGNX: -4.30 )
Ranked among companies with meaningful ROE % only.
PGNX' s ROE % Range Over the Past 10 Years
Min: -87.75  Med: -33.65 Max: 16.86
Current: -4.3
-87.75
16.86
ROA % -2.35
PGNX's ROA % is ranked higher than
84% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. PGNX: -2.35 )
Ranked among companies with meaningful ROA % only.
PGNX' s ROA % Range Over the Past 10 Years
Min: -79.08  Med: -25.15 Max: 14.53
Current: -2.35
-79.08
14.53
ROC (Joel Greenblatt) % 16.60
PGNX's ROC (Joel Greenblatt) % is ranked higher than
96% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. PGNX: 16.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1585.16  Med: -413.77 Max: 365.68
Current: 16.6
-1585.16
365.68
3-Year Revenue Growth Rate 91.50
PGNX's 3-Year Revenue Growth Rate is ranked higher than
94% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. PGNX: 91.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -55.5  Med: -16.25 Max: 91.5
Current: 91.5
-55.5
91.5
GuruFocus has detected 1 Warning Sign with Progenics Pharmaceuticals Inc $PGNX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PGNX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

PGNX Guru Trades in Q3 2016

Joel Greenblatt 48,873 sh (New)
Murray Stahl 67,200 sh (unchged)
Chuck Royce 1,728,350 sh (-9.67%)
Ken Fisher 107,663 sh (-23.30%)
Mario Gabelli 17,000 sh (-32.00%)
Paul Tudor Jones 287,813 sh (-87.71%)
» More
Q4 2016

PGNX Guru Trades in Q4 2016

Joel Greenblatt 529,614 sh (+983.65%)
Murray Stahl 67,200 sh (unchged)
Mario Gabelli Sold Out
Chuck Royce 1,459,174 sh (-15.57%)
Ken Fisher 79,028 sh (-26.60%)
Paul Tudor Jones 4,200 sh (-98.54%)
» More
Q1 2017

PGNX Guru Trades in Q1 2017

Jim Simons 243,389 sh (New)
Paul Tudor Jones 10,100 sh (+140.48%)
Joel Greenblatt 676,791 sh (+27.79%)
Ken Fisher 97,632 sh (+23.54%)
Murray Stahl 67,260 sh (+0.09%)
Chuck Royce 1,250,674 sh (-14.29%)
» More
Q2 2017

PGNX Guru Trades in Q2 2017

Ken Fisher 162,122 sh (+66.05%)
Jim Simons 291,489 sh (+19.76%)
Chuck Royce 1,346,374 sh (+7.65%)
Murray Stahl 67,260 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt 307,393 sh (-54.58%)
» More
» Details

Insider Trades

Latest Guru Trades with PGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Reduce -54.58%0.04%$6.37 - $9.44 $ 7.00-6%307,393
Ken Fisher 2017-06-30 Add 66.05%$6.37 - $9.44 $ 7.00-6%162,122
Joel Greenblatt 2017-03-31 Add 27.79%0.02%$8.32 - $11.6 $ 7.00-30%676,791
Ken Fisher 2017-03-31 Add 23.54%$8.32 - $11.6 $ 7.00-30%97,632
Joel Greenblatt 2016-12-31 Add 983.65%0.05%$4.92 - $9.57 $ 7.00-5%529,614
Ken Fisher 2016-12-31 Reduce -26.60%$4.92 - $9.57 $ 7.00-5%79,028
Mario Gabelli 2016-12-31 Sold Out $4.92 - $9.57 $ 7.00-5%0
Ken Fisher 2016-09-30 Reduce -23.30%$4.43 - $6.97 $ 7.0016%107,663
Joel Greenblatt 2016-09-30 New Buy$4.43 - $6.97 $ 7.0016%48,873
Mario Gabelli 2016-09-30 Reduce -32.00%$4.43 - $6.97 $ 7.0016%17,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CARA, NAS:VYGR, LSE:PRTC, NAS:SNNA, NAS:SYRS, NAS:AVEO, NAS:ATRA, NAS:NK, NAS:BCRX, NAS:AGEN, NAS:IOVA, NAS:JNCE, NAS:NSTG, NAS:PDLI, NAS:BLCM, NAS:ACHN, NAS:GLYC, NAS:SELB, NAS:NLNK, NAS:ASMB » details
Traded in other countries:PGP.Germany,
Headquarter Location:USA
Progenics Pharmaceuticals Inc is a biopharmaceutical company that develops innovative medicines and other technologies to identify, target and treat cancer. Its pipeline drugs include AZEDRA and 1095; 1404 and PyL; and imaging analysis tools.

Progenics Pharmaceuticals is an American biotechnology company. The company develops innovative medicines to treat cancer. Progenics Pharmaceuticals' portfolio includes AZEDRA (to treat malignant and/or recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 335.23
PGNX's Price-to-Owner-Earnings is ranked lower than
55% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. PGNX: 335.23 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PGNX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 21.83  Med: 54.61 Max: 357.62
Current: 335.23
21.83
357.62
PB Ratio 6.68
PGNX's PB Ratio is ranked lower than
61% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. PGNX: 6.68 )
Ranked among companies with meaningful PB Ratio only.
PGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.08  Med: 3.54 Max: 9.03
Current: 6.68
1.08
9.03
PS Ratio 7.83
PGNX's PS Ratio is ranked higher than
63% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. PGNX: 7.83 )
Ranked among companies with meaningful PS Ratio only.
PGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.91  Med: 7.87 Max: 177.27
Current: 7.83
1.91
177.27
Price-to-Free-Cash-Flow 140.80
PGNX's Price-to-Free-Cash-Flow is ranked lower than
68% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. PGNX: 140.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PGNX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.91  Med: 41.61 Max: 458.82
Current: 140.8
10.91
458.82
Price-to-Operating-Cash-Flow 93.90
PGNX's Price-to-Operating-Cash-Flow is ranked lower than
64% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. PGNX: 93.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PGNX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.75  Med: 34.04 Max: 278.57
Current: 93.9
10.75
278.57
EV-to-EBIT 599.32
PGNX's EV-to-EBIT is ranked lower than
70% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. PGNX: 599.32 )
Ranked among companies with meaningful EV-to-EBIT only.
PGNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.8  Med: -2.25 Max: 644.6
Current: 599.32
-50.8
644.6
EV-to-EBITDA 233.61
PGNX's EV-to-EBITDA is ranked lower than
68% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. PGNX: 233.61 )
Ranked among companies with meaningful EV-to-EBITDA only.
PGNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -132.8  Med: -2.4 Max: 251.3
Current: 233.61
-132.8
251.3
EV-to-Revenue 6.79
PGNX's EV-to-Revenue is ranked higher than
68% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. PGNX: 6.79 )
Ranked among companies with meaningful EV-to-Revenue only.
PGNX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 6.3 Max: 150.6
Current: 6.79
0.4
150.6
Current Ratio 7.28
PGNX's Current Ratio is ranked higher than
77% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. PGNX: 7.28 )
Ranked among companies with meaningful Current Ratio only.
PGNX' s Current Ratio Range Over the Past 10 Years
Min: 0.42  Med: 10.79 Max: 32.92
Current: 7.28
0.42
32.92
Quick Ratio 7.28
PGNX's Quick Ratio is ranked higher than
78% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. PGNX: 7.28 )
Ranked among companies with meaningful Quick Ratio only.
PGNX' s Quick Ratio Range Over the Past 10 Years
Min: 0.42  Med: 10.79 Max: 32.92
Current: 7.28
0.42
32.92
Days Sales Outstanding 15.58
PGNX's Days Sales Outstanding is ranked higher than
89% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. PGNX: 15.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
PGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.36  Med: 40.83 Max: 180.24
Current: 15.58
0.36
180.24

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.90
PGNX's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. PGNX: -4.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -73.6  Med: -11.25 Max: -2.1
Current: -4.9
-73.6
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 27.08
PGNX's Price-to-Net-Cash is ranked lower than
71% of the 530 Companies
in the Global Biotechnology industry.

( Industry Median: 7.61 vs. PGNX: 27.08 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.59  Med: 6.64 Max: 28.15
Current: 27.08
1.59
28.15
Price-to-Net-Current-Asset-Value 20.71
PGNX's Price-to-Net-Current-Asset-Value is ranked lower than
70% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. PGNX: 20.71 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.48  Med: 6.15 Max: 21.53
Current: 20.71
1.48
21.53
Price-to-Tangible-Book 16.00
PGNX's Price-to-Tangible-Book is ranked lower than
77% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. PGNX: 16.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.22  Med: 5.27 Max: 16.64
Current: 16
1.22
16.64
Price-to-Median-PS-Value 0.99
PGNX's Price-to-Median-PS-Value is ranked higher than
60% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. PGNX: 0.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.5 Max: 16.34
Current: 0.99
0.29
16.34
Earnings Yield (Greenblatt) % 0.16
PGNX's Earnings Yield (Greenblatt) % is ranked higher than
81% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. PGNX: 0.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -305.9  Med: -15.05 Max: 10.2
Current: 0.16
-305.9
10.2

More Statistics

Revenue (TTM) (Mil) $63.61
EPS (TTM) $ -0.06
Beta3.92
Short Percentage of Float20.26%
52-Week Range $4.60 - 11.72
Shares Outstanding (Mil)70.27

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.01 -0.68
EPS without NRI ($) -1.01 -0.68
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PGNX

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharma Sep 01 2017 
Progenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th Internatio Aug 31 2017 
Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA® Aug 31 2017 
Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update Aug 09 2017 
Progenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9 Jul 26 2017 
Progenics Pharmaceuticals Announces the Presentation of Data From Two Automated Bone Scan Index Stud Jun 02 2017 
Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update May 04 2017 
Progenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4 Apr 27 2017 
Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology Apr 20 2017 
Progenics Pharmaceuticals Announces Positive Topline Results from Registrational Phase 2b Trial of A Mar 30 2017 

More From Other Websites
Progenics Pharmaceuticals to Present at the Cantor Fitzgerald 2017 Global Healthcare Conference Sep 20 2017
What's Behind Progenics Pharmaceuticals, Inc.'s Bump Today? Sep 18 2017
3 Biotech Stocks I'd Buy Right Now Sep 15 2017
ETFs with exposure to Progenics Pharmaceuticals, Inc. : September 14, 2017 Sep 14 2017
Progenics Pharmaceuticals, Inc. :PGNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13,... Sep 13 2017
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US :... Sep 12 2017
Progenics Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PGNX) : September 2, 2017 Sep 01 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics... Sep 01 2017
Progenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th... Aug 31 2017
Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA® Aug 31 2017
Progenics Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PGNX-US :... Aug 30 2017
Progenics Pharmaceuticals, Inc.: Gathering momentum, can it sustain its performance? Aug 29 2017
3 Beaten-Up Biotech Stocks: Are They Bargains? Aug 14 2017
Edited Transcript of PGNX earnings conference call or presentation 9-Aug-17 12:30pm GMT Aug 12 2017
Progenics reports 2Q loss Aug 09 2017
Here's Why Progenics Pharmaceuticals, Inc. Lost Ground Today Aug 09 2017
Progenics Pharmaceuticals Announces Second Quarter 2017 Financial Results and Business Update Aug 09 2017
Investor Network: Progenics Pharmaceuticals, Inc. to Host Earnings Call Aug 09 2017
ETFs with exposure to Progenics Pharmaceuticals, Inc. : August 4, 2017 Aug 03 2017
Progenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9 Jul 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}